| Literature DB >> 34309774 |
Cristiane Garbinato1, Cássia Alves Lima-Rezende1,2, Sabrina Ester Schneider3, Jefferson Pedroso3, Aline E Dos Santos4, Fernanda Petry1, Gean Pablo S Aguiar1, Liz Girardi Müller1, Marcelo Lanza4, Angelo Piato5, J Vladimir Oliveira1,4, Anna Maria Siebel6,7.
Abstract
Epilepsy affects around 50 million people worldwide, and an important number of patients (30%) fail to respond to any available antiepileptic drug. Previous studies have shown that luteolin presents a promising potential as an anticonvulsant. On the other hand, different studies showed that luteolin does not promote anticonvulsant effects. Therefore, there is a lack of consensus about the use of luteolin for seizure control. Luteolin low bioavailability could be a limiting factor to obtain better results. Attractively, micronization technology has been applied to improve flavonoids bioavailability. Thus, the present study aimed to investigate the effects of luteolin on its raw form and micronized luteolin in a PTZ-induced seizure model in adult zebrafish (Danio rerio). Our results demonstrate that luteolin and micronized luteolin did not block PTZ-induced seizures in adult zebrafish. Also, luteolin and micronized luteolin did not provoke behavioral changes. Finally, our results show that 24 h after seizure occurrence, no changes were detected for p70S6Kb, interleukin 1β, and caspase-3 transcript levels. Altogether, we failed to observe an anticonvulsant potential of luteolin in adult zebrafish, even in its micronized form. However, we recommend new studies to investigate luteolin benefits in epilepsy.Entities:
Keywords: Epilepsy; Luteolin; Micronization; Seizure; Zebrafish
Mesh:
Substances:
Year: 2021 PMID: 34309774 DOI: 10.1007/s11064-021-03409-8
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996